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Abstract
Purpose The constructs evaluated in investigating association between psychosocial factors and cancer survival has varied 
between studies, and factors related to quality of life (QOL) have shown contradictory results. We investigated the effect 
of socioeconomic and early QOL and psychological factors on disease-free time and survival in localized prostate cancer.
Methods A consecutive sample of patients with localized prostate cancer (T1–3, N0, M0) treated with external beam 
radiotherapy completed validated questionnaires on coping with cancer (the Ways of Coping Questionnaire WOC-CA), 
anger expression (the Anger Expression Scale), life events (the Life Experience Survey), and various aspects of QOL (the 
Rotterdam Symptom Checklist, the Depression Scale DEPS, the EORTC QLQ-C30, the LENT-SOMA outcome measure) 
approximately 4.5 months after diagnosis. Cox regression analyses were used to determine the predictors of the disease-free 
and overall survival times measured from the date of diagnosis to the date of a PSA-relapse and date of death.
Results After controlling for biological prognostic factors, age, and adjuvant hormonal therapies, moderate and high socio-
economic status and an increased level of pain predicted longer survival, whereas an increased level of prostate-area symp-
toms and fatigue and, especially, reports of no/few physical symptoms were predictors of a shorter survival time. A longer 
PSA-relapse-free time was predicted by Cognitive Avoidance/Denial coping, whereas problems in social functioning, hope-
lessness, and an excellent self-reported QOL predicted a shorter PSA-relapse-free time.
Conclusions Higher socioeconomic status was prognostic for longer survival, as previously reported. Patients with a seem-
ingly good QOL (few physical complaints, excellent self-reported QOL) had poorer prognoses. This association may due 
to the survival decreasing effect of emotional non-expression; patients with high emotional non-expression may over-report 
their wellbeing in simple measures, and thus actually be in need of extra attention and care.
Keywords Disease-free time · Emotional non-expression · Patient-reported quality of life · Prostate cancer · Socioeconomic 
status · Stress, Psychological · Survival
Introduction
The association between psychosocial factors and cancer 
survival has been convincingly demonstrated only during 
recent decades [1–12]. The psychological processes and 
constructs investigated have varied among studies [4, 8]. 
Many of the earlier studies were retrospective, biological 
prognostic factors were not sufficiently controlled for, and 
only certain factor(s) were investigated. In many of the pro-
spective studies, the survival follow-up time was very short 
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[4, 8–10, 13, 14]. In addition, socioeconomic factors were 
not often taken into account [4, 15, 16].
Studies suggest that some psychosocial factors, such as 
emotional expression and psychological stress, are more 
likely to have an effect on survival compared with other 
factors [4]. Specifically, emotional non-expression (“repres-
sion”) [6, 17–19], hopelessness [7, 20, 21], depression [1, 
10, 11, 20], and stress-related psychological factors [8, 
12, 20] have been suggested to predict a shorter survival, 
whereas social support [22] and denial or minimizing coping 
response to the cancer to predict a more favorable prognosis 
[2, 5–8, 12, 21]. Factors related to well-being and quality of 
life (QOL) have shown contradictory results [2, 5–7, 9, 23]. 
In some studies, a good reported QOL has shown an associa-
tion with a poorer prognosis [6, 7, 9].
Among the number of studies investigating the impact of 
psychosocial factors on cancer progression, very few have 
dealt with prostate cancer. However, prostate cancer is the 
most common cancer among men in developed countries, 
including Finnish men (http://www.cance rregi stry.fi). In 
most countries, the average age at prostate cancer diagnosis 
is greater than 70 years. The incidence is increasing world-
wide in part due to the aging populations and the widespread 
testing for prostate-specific antigen (PSA) [24–27]. Today, 
most prostate cancers are detected when they are localized 
or at most locally invasive, and the prognosis is generally 
good [24–28].
A major limitation of many previous studies was that 
the effect of psychosocial factors has been investigated 
in isolation from other related factors or processes [4, 13, 
29–31]; however, the effect of these factors does not occur 
in isolation. Investigating their impacts separately results 
in over-simplification and misleading results. In particular, 
connections between coping and personality processes are 
important [18, 32, 33]. Therefore, the effect of psychologi-
cal and psychosocial factors and their relative impact can 
be identified only when several factors are investigated and 
analyzed jointly, adjusting their effects on each other.
The psychobiological mechanisms that are thought to 
have an impact on cancer survival are related to psycho-
logical stress [4, 8, 34, 35]. According to psychological 
stress theories, the effects of stress on health outcomes 
depend on how a person can cope with the stress, cop-
ing being the main mediator in the process from stressful 
events to outcomes such as psychological symptoms and 
somatic illness [36, 37]. Social support and personality 
factors modify the coping process [38]. In the process-ori-
ented view [36, 37, 39], coping is defined as “the person’s 
constantly changing cognitive and behavioral efforts to 
manage specific external and/or internal demands that are 
appraised as taxing or exceeding the person’s resources.” 
There are no in built assumptions on good or bad coping. 
The actual coping process refers to the person’s efforts to 
reduce, minimize, master or tolerate the person–environ-
ment transaction that has been appraised to be demanding. 
Psychological stress processes have been linked with bio-
logical immune down-regulation in cancer [34].
According to a model proposed to guide research in 
psycho-oncology [33], the impact of cancer disease and 
treatment effects are mediated by personal (including 
personality and coping style, adjustment, and sociode-
mographic factors), medical, social-environmental, and 
life stressor factors [3, 12, 29, 33]. The outcomes of these 
pathways are QOL and survival. In particular, a personal-
ity-related coping response called non-expression of nega-
tive emotion is potentially associated with poorer cancer 
progression [4, 7, 17–19, 40]. Non-expression of nega-
tive emotion refers to a tendency to suppress (i.e., not to 
express) negative feelings [17, 32], such as anger and fear, 
and leads to less effective coping in stressful situations. It 
has been described as being emotionally contained and 
“maintaining a facade of contentment” in social relation-
ships. Related concepts, such as emotional defensiveness 
(antiemotionality, i.e., suppression and control of emo-
tions) has also been found to predict reduced survival in 
cancer [6, 17]. Furthermore, there is a suggested cancer-
prone Type C response style [18, 19], which is a mul-
tidimensional construct that includes non-expression of 
negative emotions as a core element, where helplessness/
hopelessness in stressful situations, and self-sacrificing, 
over-cooperative, and appeasing behavior are added. Type 
C response style has been found to be associated with 
reduced survival in cancer.
We previously presented a conceptual model on the psy-
chosocial predictors of wellbeing of cancer patients [35]. In 
the model, we assume that both QOL and survival are out-
comes in a stress process, which is mediated by psychologi-
cal stress processes and initiated by cancer and treatment. 
Coping with cancer is the main mediator in the process, 
and social support and personality factors modify the coping 
process. Furthermore, we assume that these processes are 
interfered by non-cancer life stresses. We previously applied 
the model for studying baseline psychosocial predictors of 
survival outcomes in localized melanoma [7, 12] and breast 
cancer [6] patients under 72 years of age. We identified some 
gender differences, indicating that men may respond to dif-
ferent types of psychosocial factors compared with women 
[12].
In the present study, on the basis of the model and experi-
ences from our previous studies, we investigated the base-
line and early predictors of disease-free and overall survival 
times in prostate cancer patients of all ages and treated with 
external beam radiotherapy in Finland. We hypothesized 
that specific factors in the psychological stress processes 
(patterns of coping, anger expression traits, non-cancer life 
events), and components of patient-reported QOL evaluated 
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at the time of primary treatment are associated with disease-
free time and survival in localized prostate cancer.
Methods
Patients and procedure
Newly diagnosed T1–3, N0, M0 prostate cancer patients 
who were admitted for treatment to the Department of 
Oncology, Tampere University Hospital (Finland) in 2002 
and were treated with curative external beam radiotherapy 
were consecutively included as eligible patients for the study 
(n = 104). Patients who were mentally and physically able to 
participate in a study interview and complete questionnaires 
(no active severe mental or neurological disease) and with 
no previous cancer disease1 were invited to participate; 6 
patients were not invited because they could not be inter-
viewed (3 dementia, 2 consequences of stroke, and 1 acute 
state of another physical illness), and 3 patients based on a 
previous cancer. Six patients refused to participate. In the 
end, 89 patients (86%) were interviewed. An additional 3 
patients were excluded from the survival analyses because 
they had a T4 disease, and 5 patients because they had 
underwent radical prostatectomy prior to the radiotherapy. 
Thus, the final study group comprised 81 patients (Table 1).
In Finland, hospital districts organize specialized medical 
care. Some specialized medical care services, e.g., oncology, 
are organized on the basis of special responsibility areas 
of the five university hospitals of Finland. Because of this 
centralized cancer care, nearly all patients diagnosed in the 
region and treated with external beam radiotherapy were 
included in the eligible patients.
The patients were interviewed at approximately 
4.5 months (range 2–9) after diagnosis by the same inter-
viewer (a medical student, the third author) during a visit to 
the Department of Oncology for external beam radiotherapy. 
A patient was not interviewed until two months after the 
diagnosis to avoid disturbing the patients in an acute can-
cer crisis and to achieve a more reliable measurement, and 
each patient was currently receiving external radiotherapy 
(65% with LHRH analog as neo-adjuvant hormonal ther-
apy). Each interview took approximately 1.5–2.5 h. Dur-
ing the interview the patients completed several validated 
questionnaires addressing various psychological factors and 
aspects of patient-reported well-being and QOL (see, Meas-
ures, below). The patients were also asked to report their 
demographics, vocational education, and family income. 
Most of the measures were the same as used in our previous 
Table 1  Demographic, socioeconomic, disease, and treatment vari-
ables in patients
Variable N = 81 (%)
Age, mean 66.5 years (median 68, range 51–82 years)
 50–59 10 (12)
 60–69 48 (59)
 70–79 22 (27)
 > 80 1 (1)
Marital status
 Single 1 (1)
 Married or cohabiting 68 (84)
 Divorced 7 (9)
 Widowed 5 (6)
Children, mean 2.3
 Have children 75 (93)
 Vocational education
 None 33 (41)
 Vocational courses 7 (9)
 Vocational school 17 (21)
 College 17 (21)
 University education (any) 7 (9)
Yearly family income (EUR)
 < 17,000 19 (23)
 17,000–25,000 22 (27)
 25,000–34,000 19 (23)
 34,000–42,000 10 (12)
 > 42,000 11 (13)
Socioeconomic status (SES)
 Low 12 (15)
 Moderate 57 (70)
 High 12 (15)
Gleason classification (x + x)
 3–4 9 (11)
 5 9 (11)
 6 28 (35)
 7 21 (26)
 8 7 (9)
 9–10 4 (5)
 Unidentified 3 (4)
Tumor classification
 T1 28 (35)
 T2 29 (36)
 T3 24 (30)
Biological  riska
 Low 28 (35)
 Moderate 31 (38)
 High 22 (27)
Radiation
 Total dose Mean 69.9, range 
68.0–70.4
 Radiation for pelvic lymph nodes 8 (10)
1 A previous cancer was anticipated to influence the psychological 
stress processes that were the initial research target.
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melanoma [7, 12] and breast cancer [6] survival studies, but 
two health-related QOL measures (the EORTC QLQ-C30 
[41] and the LENT-SOMA outcome measure [42]) were 
added in the present sample.
Measures
Cancer and treatment data (staging, Gleason classification, 
neo-adjuvant hormonal therapy, and adjuvant hormonal ther-
apy; Table 1) and survival time and disease-free time data 
(date of diagnosis, date of death, date of PSA-verification 
of recurrence of the cancer) were obtained from hospital 
medical records.
Socioeconomic status was operationalized as a combi-
nation of vocational education and yearly family income 
(total income of the household). It was classified as ‘low᾽ 
if the patient had no occupational education and the yearly 
income was < 17,000 EUR, ‘moderate᾽ if the income was 
17,000–34,000 EUR, and ‘high᾽ if the patient had a col-
lege or university education and/or the yearly income was 
≥ 34,000 EUR (Table 1).
The measured psychological/psychosocial and QOL 
domains are listed below:
1. Coping with cancer was measured using the Ways of 
Coping Questionnaire (WOC), a 50-item self-report 
questionnaire (scale 0–3 in every item) developed “to 
identify the thoughts and actions an individual has 
used to cope with a specific stressful encounter”—here 
any aspect of the prostate cancer since the diagnosis. 
We used an item structure proposed to form a cancer-
specific WOC-CA measure [43, 44], including the pat-
terns Focusing on the Positive, Distancing, Seeking and 
Using Social Support, Cognitive Avoidance, and Escape 
Avoidance.
2. The traits of anger expression were evaluated using the 
Anger Expression Scale (AX Scale) [45]. It refers to “the 
extent that an individual engages in aggressive behav-
iors when motivated by angry feelings” and taps three 
dimensions: Anger-in (“individual differences in the 
frequency that angry feelings are experienced but held 
in”), Anger-out (“...feelings of anger are expressed in 
aggressive behavior”), and Anger control (“...an individ-
ual attempts to control the outward expression of angry 
feelings”).
3. Stressful life events were recorded from the preceding 
year using the Life Experience Survey (LES) [46], a list 
of 50 events addressing both the number of life events 
and their perceived impact.
4. To measure patients’ symptoms and their intensity, 
we used the Rotterdam Symptom Checklist (RSCL) 
[47], which has been developed to measure symptoms 
reported by cancer patients. The RSCL includes 30 
symptoms (8 psychological and 22 physical, scale 0–3 
in every symptom) that the patients may have experi-
enced during the past week and a separate single item 
index on overall global quality-of-life with scale from 1 
(extremely poor) to 7 (excellent). The level of depressive 
symptoms was measured using the Depression Scale 
DEPS [48], which has been developed for screening of 
depression in primary health care settings and evaluates 
10 feelings and depressive symptoms (scale 0–3) with 
a coverage-period of the previous month. One of the 
DEPS symptoms is hopelessness.
5. Health-related QOL of the patients was measured using 
the European Organization for Research and Treat-
ment of Cancer Quality of Life Questionnaire (EORTC 
QLQ-C30)2 version 3.0, Finnish translation [41]. The 
measure is divided into a global health status scale, five 
functional scales (Physical/Role/Emotional/Cognitive/
Social functioning) and several symptom scales/items, 
e.g., fatigue, nausea, and pain; all evaluated from the 
previous week. Local prostate-area symptoms were eval-
uated using a modification of the LENT-SOMA outcome 
measure (see Footnote 2) [42], a clinical tool developed 
to record and score normal tissue effects of radiotherapy 
(urinary, bowel, and sexual symptoms and dysfunction).
The study protocol was approved by the ethical commit-
tee of Tampere University Hospital, and informed consent 
was obtained from each participant. The first author is bound 
by national (The Union of Finnish Psychologists) and inter-
national (American Psychological Association) ethical codes 
of psychology.
The hospital district was ethnically homogeneous regarding the age 
groups in question
a According to nomogram for prostate cancer recurrence [50]: clas-
sified as ‘Low risk’ if Gleason ≤ 6 and PSA < 10, ‘Moderate risk’ 
if Gleason = 7 or PSA 10–20, and ‘High risk’ if Gleason ≥ 7 or 
PSA > 20
Table 1  (continued)
Variable N = 81 (%)
Neo-adjuvant hormonal therapy
 None 28 (35)
 LHRH analog 53 (65)
Adjuvant hormonal therapy
 Yes 34 (42)
Other chronic disease/condition
 Yes 66 (81)
2 The EORTC QLQ-C30 and the LENT-SOMA outcome measure 
were not used in our previous survival studies.
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Statistical analyses
Descriptive statistics, ANOVA, t test, and Pearson’s cor-
relation (r), were used to explore the sample. Regression 
analysis was used to investigate the association between 
background factors, psychological/psychosocial factors, and 
the QOL indicators. The Cox proportional hazards regres-
sion model [49] was used to determine the simultaneous 
and relative contribution of the socioeconomic, psychologi-
cal, and QOL predictors on disease-free and overall survival 
times, controlled for age, biological prognostic factors, and 
hormonal treatment. The predictor variables were separately 
tested for both outcomes. Predictors of the survival times 
in the Cox models were considered significant if the cor-
responding p-value was < 0.05.
Overall survival was measured from the date of diagnosis 
(date of PAD) to the date of death and disease-free time from 
the date of diagnosis to the date of a PSA-verified relapse, 
or the survival was censored at the date of last follow-up 
(March 31, 2011). A biological risk classification into mild, 
moderate, and severe for T1–2 tumors [50] (Table 1, foot-
note a) and separately T3 tumors was used as a biological 
prognostic factor. Implementation of neo-adjuvant hormonal 
therapy and adjuvant hormonal therapy were used as prog-
nostic treatment factors.
In the Cox models, age, biological prognostic factors, and 
treatment (the hormonal therapies) were always included 
in the models. Second, we added the socioeconomic status 
variable(s) to the models to investigate their impact, and 
adjust for their effect when investigating the effects of the 
other variables. Third, the psychological and QOL indica-
tors (see Measures; selected on the basis of the theoretical 
model [35]) were added into the models individually and in 
various combinations, and following experiences from our 
previous corresponding studies. To avoid testing of related 
variables, we investigated their psychometric properties and 
mutual associations, and selected the variables that were the 
best (high Cronbach’s Alpha, symmetrical distribution) and 
were least correlated with each other. In some variables, we 
divided the answer options into two categories (no/yes). The 
proportional hazard assumption was tested [51] for specific 
variables and globally. Statistical analyses were performed 
using SPSS for Windows 18 and 20, and Stata 11 (Stata-
Corp. 2013. Stata Statistical Software: Release 13. College 
Station, TX: StataCorp LP, USA).
Results
By April 2011, eighteen (22%) of the 81 patients had died, 
and the follow-up time was ≥ 8 years 4 months (median 8.54 
years, 95% CI 31.01–31.25 days; no patients were lost from 
the overall survival follow-up). Information on progression 
of the prostate cancer, i.e., PSA follow-up was available for 
77 patients, and 18 (23%) of them had been diagnosed with 
PSA verification of prostate cancer relapse. Five patients 
with relapse had died.
Association between the psychological and QOL 
variables
According to our theoretical model [35] (see, Introduction), 
we investigated first the association between the potential 
predictor variables (background and disease/treatment vari-
ables, anger expression, and coping) and the wellbeing/QOL 
indicators. All the QOL indicators were strongly intercorre-
lated (p-values generally < 0.001). Therefore, we separately 
investigated predictors of the RSCL and the EORTC QLQ-
C30 subscales, and the DEPS. On the whole, the disease and 
treatment variables did not associate with QOL, whereas 
the coping and anger expression variables were associated 
with several wellbeing and QOL indicators. Higher income 
of the family predicted more psychological symptoms and 
problems in Role functioning, Emotional functioning, and 
Cognitive functioning. Escape coping was associated with 
a poorer and Distancing coping with a better psychologi-
cal health and self-perceived QOL, as measured by all the 
indicators. The Anger-in trait was associated with poorer 
wellbeing, whereas Anger control was associated with better 
wellbeing when evaluated by any of the measures despite 
social functioning.
Predictors of overall survival and disease‑free time
T3 tumor (HR 5.51, 95% CI 0.88–34.45, p = 0.07) and neo-
adjuvant hormonal treatment (HR 0.26, 95% CI 0.05–1.31, 
p = 0.1) were only weakly associated with overall survival. 
Disease-free time was not significantly predicted by any of 
the disease and treatment variables.
Individual associations between the predictor 
variables and survival outcomes
Lack of vocational education showed an individual asso-
ciation with both shorter survival and disease-free times, 
and low family income was associated with shorter survival 
(Table 2). Some indicators of a good QOL were individu-
ally associated with poorer outcomes: low level of reported 
physical symptoms (the lowest 18.5% vs. the remaining) 
was associated with both shorter survival and disease-free 
times, and the highest score in the single-item quality-of-life 
index (‛excellent’, reported by 18.2%) was associated with a 
shorter disease-free time. Furthermore, increased pain and 
reported number of life events were individually associated 
with longer survival.
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Simultaneous impacts of the predictor variables 
on overall survival
Patients’ moderate and high socioeconomic status predicted 
longer overall survival when adjusted for the biological and 
treatment variables, with multivariate hazard ratios of 0.16 
(95% CI 0.05–0.46, p = 0.001) and 0.11 (95% CI 0.02–0.6, 
p = 0.015), respectively.
When the psychological and QOL variables were added 
to the model, we found that a complex combination of vari-
ables predicted overall survival (Table 3). Different QOL 
measures exhibited either a favorable or an unfavorable 
impact, i.e., an increased level of pain (HR 0.05; 95% CI 
0.01–0.32) predicted longer survival, whereas prostate-area 
symptoms (HR 1.18; 95% CI 1.03–1.36), increased fatigue 
(HR 7.08; 95% CI 1.77–28.32), and reports of no or few 
physical symptoms (HR 9.90; 95% CI 1.48–66.30) were sig-
nificant predictors of shorter survival time. However, when 
the overall quality-of-life index (total scale 1–7) was tested 
instead of the prostate-area symptom scale, it predicted a 
longer survival (HR 0.51, 95% CI 0.27–0.95, p = 0.033); 
when both scales were included, the effect of the overall 
QOL was weaker (HR 0.56; 95% CI 0.27–1.15, p = 0.113).
Simultaneous impacts of the predictor variables 
on PSA‑relapse‑free time
The PSA-relapse-free time was not significantly predicted 
by any of the biological prognostic factors, hormonal treat-
ment, or socioeconomic status. A longer disease-free time 
was predicted by Cognitive Avoidance/Denial coping (HR 
0.76; 95% CI 0.59–0.97), whereas a shorter relapse-free time 
was seen for patients with problems in social functioning 
(HR 3.32; 95% CI 1.45–7.56), hopelessness (HR 8.90; 95% 
CI 1.62–48.87), and an excellent self-reported QOL (HR 
47.31; 95% CI 6.35–352.33) (Table 4).
Table 2  Measures with 
statistically significant 
individual associations with 
overall survival time and 
disease-free time
HR hazard ratios in Cox models: impact of each predictor analyzed individually and adjusted for age, bio-
logical prognostic factors and adjuvant hormonal therapies
a Physical symptoms scale (RSCL) low = score < 7 (18.5%) versus the remaining scores. When the scale 
was divided into two levels based on the median, the higher level was associated with a longer overall sur-
vival with HR 0.43, p = 0.1
b In the RSCL quality-of-life index (1–7) the highest score 7 ‘excellent’ (18.2%) versus the remaining scores
c A scale in the EORTC QLQ-C30
d By the LES
Individual predictors Univariate analyses
Association with overall sur-
vival time
Association with PSA-
relapse-free time
HR (95% CI) p HR (95% CI) p
No vocational education 2.78 (1.02–7.59) 0.046 2.40 (0.89–6.46) 0.083
Family income low (< 17,000) 4.85 (1.69–13.90) 0.003 n.s
Level of physical symptoms low, no/yesa 5.99 (2.02–17.77) 0.001 3.21 (0.96–10.72) 0.058
Self-reported QOL ‘excellent’, no/yesb n.s 5.21 (1.81–14.95) 0.002
Painc 0.20 (0.05–0.83) 0.026 n.s
No. of non-cancer life  eventsd 0.71 (0.51–1.00) 0.048 n.s
Table 3  Psychosocial and QOL measures at the time of curative radi-
otherapy predicting overall survival
HR hazard ratios in the Cox model; all variables were adjusted for 
each other
a Based on the RSCL Physical symptoms scale: the lowest 18.5% ver-
sus the remaining scores
b A scale in the EORTC QLQ-C30
c The LENT-SOMA scale. When the RSCL overall quality-of-life 
index (1–7) was tested instead of the LENT-SOMA prostate-area 
symptoms, its relative HR was 0.51 (95% CI 0.27–0.95, p = 0.033)
Predictor Multivariate analysis
HR (95% CI) p
Age, years 0.98 (0. 89–1.07) 0.599
Biological risk
 Moderate risk in Tumor 1–2 0.15 (0.02–0.97) 0.047
 High risk in Tumor 1–2 0.52 (0.06–4.64) 0.562
T3 Tumor 4.98 (0.63–39.29) 0.127
Neo-adjuvant hormonal therapy, no/yes 0.17 (0.02–1.21) 0.076
Adjuvant hormonal therapy, no/yes 1.54 (0.24–9.77) 0.649
Socioeconomic status
 Moderate 0.20 (0.04–0.91) 0.037
 High 0.04 (0.01–0.34) 0.003
Level of physical symptoms low, no/yesa 9.90 (1.48–66.30) 0.018
Painb 0.05 (0.01–0.32) 0.002
Urinary, bowel, and sexual symptoms c 1.18 (1.03–1.36) 0.017
Fatigueb 7.08 (1.77–28.32) 0.006
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The proportional hazard assumption was successfully 
tested for the final models locally and globally using Sch-
oenfeld residuals [51], indicating that these impacts remain 
stable over the follow-up period.
Discussion
Overall survival and disease-free time in patients with local-
ized prostate cancer were predicted by socioeconomic sta-
tus, psychological factors, and patient-reported QOL. Dif-
ferent QOL measures demonstrated contradictory results as 
either a favorable or an unfavorable impact. Surprisingly, 
we found that the patients’ reports of no or few physical 
complaints predicted shorter survival, whereas reported 
pain was prognostic for longer survival. In addition, a longer 
PSA-relapse-free time was predicted by responding to the 
cancer diagnosis with a Cognitive Avoidance/Denial coping 
pattern, whereas problems in social functioning, hopeless-
ness, and—contradictorily—reporting an excellent QOL, 
predicted a shorter PSA-relapse-free time. We suggest 
an explanation for these surprising findings, i.e., that the 
observed survival decreasing effect of high scores in certain 
simple QOL measures may reflect a trait of non-expression 
of negative emotions (a tendency not to express negative 
feelings and to keep ‘facade of contentment’), that has been 
found potentially associate with cancer progression. We pro-
pose that the patients who scored exceptionally low/high in 
simple wellbeing/QOL measures may have been those with 
high non-expression of negative emotions and that they thus 
over-reported their wellbeing.
Few earlier studies on psychosocial factors and cancer 
survival have addressed prostate cancer [8, 52, 53] or male 
patient samples that also include the oldest age-groups. 
We were able to collect a relatively small but regionally 
representative sample of newly diagnosed prostate cancer 
patients. At the time of the data collection, the prostate 
cancer therapy was different than today (e.g., active sur-
veillance was hardly used) and the active treatment modes 
have improved ever since. There were no population PSA-
screening programs going on in Finland. The study sample 
was limited to patients who underwent curative radiotherapy, 
and the other major definite therapy mode, radical prostatec-
tomy, was not represented. However, younger and healthier 
patients more often undergo operation, whereas external 
radiation is received by a wider patient cohort [54]. For prac-
tical reasons, the timing of the measurement since diagnosis 
varied (2–9 months); the onset of the radiotherapy differed, 
and the patients were willing to take part to the interview at 
different time points during their radiotherapy.
We investigated both overall survival and disease-free 
times because they are very different outcomes in cancer 
types with good prognoses, such as prostate cancer, and may 
thus be predicted by different mechanisms; we found that 
they were indeed predicted by different factors. The potential 
predictors were simultaneously investigated to account for 
their relative impact, and were either derived from a theoreti-
cal model [35] or were previously demonstrated to exhibit 
an association with cancer survival [4, 20, 33]. Most of the 
predictor variables were subscales of established validated 
questionnaires. The radiotherapy was currently going on in 
all patients. The analyses were carefully adjusted for age, 
known biological prognostic factors, and treatment.3
We found that a higher socioeconomic status predicted a 
longer survival both independently and when evaluated with 
the psychological and QOL factors. The survival prolonging 
effect of socioeconomic status in cancer is well known [15, 
16, 55], and has been previously reported in prostate cancer 
patients receiving curative treatment [53]. However, previ-
ous studies often considered its effect alone without other 
potential predictors [52, 53, 56]. We concur with previous 
studies suggesting that socioeconomic status should be taken 
into account to obtain valid information on the impact of 
QOL on survival in prostate cancer [57].
The measures associated with poorer outcomes appeared 
to be the simple indicators of self-reported wellbeing, i.e., 
low scores in perceived physical symptoms and an excel-
lent score in an overall QOL index. We did not find nega-
tive association between established QOL measures and 
Table 4  Psychosocial and QOL measures at the time of curative radi-
otherapy predicting PSA-relapse-free time
HR hazard ratios in the Cox model; all variables were adjusted for 
age, biological risk, hormonal therapies, and SES (which were all sta-
tistically non-significant), and were adjusted for each other
a Cognitive avoidance coping was statistically significant only when 
all the other variables were included in the model
b Based on the RSCL quality-of-life index (1–7): the score ‘excellent’ 
(= 7) versus the remaining scores
c The EORTC QLQ-C30. When Anger-in personality trait was tested 
instead of the social functioning, it showed HR of 1.15 (95% CI 0.98–
1.37, p = 0.1)
Multivariate analysis
HR (95% CI) p
Cognitive avoidance/denial  copinga 0.76 (0.59–0.97) 0.031
Self-reported QOL ‘excellent’, no/
yesb
47.31 (6.35–352.33) < 0.001
Hopelessness, no/yes 8.90 (1.62–48.87) 0.012
Problems in social  functioningc 3.32 (1.45–7.56) 0.004
3 As expected, having a locally invasive tumor (T3) predicted a 
shorter survival when compared with fully localized disease, and neo-
adjuvant hormonal therapy was effective.
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the survival outcomes, or if there was an association, it was 
positive. We suggest that these results may reflect the harm-
ful effect of non-expression of negative emotions, which 
has been defined to refer a tendency not to express negative 
feelings and to keep ‘facade of contentment’[17]. Accord-
ing to this theory, individuals with high non-expression of 
negative emotions potentially under-report their symptoms 
as they are prone to a repressive coping style, i.e., tend to 
avoid a negative affect, and consequently answer wellbeing 
measures overly positively [17, 32]. This idea was supported 
by the finding that the Anger control personality trait was 
associated with less reported symptoms and a better QOL.
One supporting factor to our argument is that scoring 
low in symptom measures and very high in overall QOL 
at the time of recent cancer diagnosis and ongoing radia-
tion treatment may not reflect the true objective situation. 
Instead, these scores may reflect a personality trait or coping 
behavior at a stressful situation (recent cancer diagnosis, 
ongoing radiotherapy). Furthermore, when e.g., the quality-
of-life index was tested as a total scale (very poor–excellent) 
it predicted a longer survival. So, our results did not indicate 
that reporting a good QOL was hazardous, but that report-
ing an ‘excellent’ QOL was. Individuals with a repressive 
coping style have also previously been found to score low 
in self-reported physical symptom scales [58]. Up to 20% of 
the population has been found to answer self-report scales in 
an overly positive fashion [32], which corresponds with our 
finding that the hazardous effect on survival was identified 
when the scores were divided into two categories: no/very 
few symptoms or an ‛excellent’ QOL versus other (both were 
present in approximately 18% of the patients).
The results obtained on simple wellbeing/QOL indica-
tors support the conclusions we have made in our previous 
studies [6, 7], i.e., that simple global-rating methods are 
not suitable of eliciting information on QOL of all cancer 
patients. Certain subgroups (“repressors”) seem to under-
state their condition and over-report their wellbeing. There is 
a risk that the simple global-rating measures actually provide 
more information on non-expression of negative emotions 
behavior than QOL. It has been suggested [32] that to elicit 
information from repressors measures requiring specific 
answers should be used instead of single-item indexes or 
symptom lists.
Prostate-area symptoms (urinary, sexual, bowel) and 
fatigue—as evaluated with well-established validated meas-
ures comprising specific questions—were prognostic for 
shorter survival, as expected. These are common adverse 
effects in external radiation and are likely to be well recorded 
at the oncology clinic, and patients may be less likely to 
under-report them. This measurement was, however, not 
congruent because the timing of the interview during the 
radiotherapy varied, which potentially affects the level of 
side effects. However, the survival model also held when 
the overall QOL index (total score 1–7) was tested instead of 
the prostate-area symptoms. These factors both indicated the 
wellbeing/ill-being of the patient during the primary treat-
ment. Self-evaluation of the wellbeing status is continuously 
presented to be a reliable indicator of an individual’s current 
and future health.
The obtained results on problems in social functioning 
and hopelessness, and a shorter relapse-free time may also 
relate to concepts close to non-expression of negative emo-
tions, such as antiemotionality (“emotional defensiveness”) 
[17] and Type C response style [18, 19]. Antiemotionality 
(suppression and control of emotions) is manifested in self-
sacrificing behavior, which may eventually lead to problems 
in social functioning. Helplessness/hopelessness in stressful 
situations is a component of the Type C style. We previously 
found that antiemotionality predicted shorter survival in 
breast cancer [6] and hopelessness in melanoma [7]. Hope at 
cancer diagnosis is essential [59] and it may predict survival 
[1, 11]. Hopelessness has been found to affect cancer mortal-
ity at the population level [60], especially in older popula-
tions [61], to which most prostate cancer patients belong. 
Moreover, the observed favorable effects of pain and num-
ber of stressful life events may be related to non-existence 
of non-expression of negative emotions: those without may 
have reported more symptoms and events.
In accordance with our previous studies [6, 7, 12], we 
identified only one protective psychological factor: the Cog-
nitive Avoidance/Denial coping pattern, and it predicted 
only the disease-free time. As noted above, overall survival 
and PSA-relapse-free time are very different outcomes in 
prostate cancer; the former is less affected by the cancer 
because of the good prognosis, whereas the latter is cancer-
specific. This result is in line with cumulating research sug-
gesting that a favorable prognosis in cancer is predicted by 
responding to the cancer diagnosis by a coping pattern of 
denying [21] or, nowadays more often called, ‘minimizing’ 
the fact of having cancer [1, 2, 4–7, 17, 20, 29]. This concept 
refers, according to definition of coping, the patients’ efforts 
to manage demands caused by the cancer by minimizing 
impact of the disease, not the consequent negative affect. 
However, denying/minimizing may at a later point of time 
have a different effect [59].
Our results provide an explanation for why good self-
reported QOL in some previous studies appeared to have 
had an unfavorable impact on cancer survival outcomes. 
Patient reports of a good wellbeing in simple measures may 
reflect non-expression of negative emotions. Thus, very high 
reports of wellbeing in newly diagnosed cancer patients may 
indicate a psychological risk factor for reduced survival out-
comes. It may be good for the patients to have complaints 
at the time of primary treatment. This finding may have 
clinical relevance given that patients who report no or few 
problems (no symptoms, excellent QOL) may actually be 
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vulnerable and in need of extra attention and care. How-
ever, more research is needed, e.g., to investigate the issue 
in patients with different cancer types/different diseases, in 
both genders, in different phases of care and rehabilitation, 
and in prospective designs.
Clinicians are to interpret scores of validated question-
naires on wellbeing and QOL as usual. A clinician who 
interprets the scores should know the patient’s situation, e.g., 
phase of treatment and time since diagnosis. Conclusions 
of the patients’ wellbeing should not be based on a single 
measurement. Validated questionnaires are good tools for 
screening of state of QOL, which may require further clini-
cal examination. Our criticism is targeted to simple QOL 
indicators which are easily influenced by other factors, e.g., 
non-expression of negative emotions.
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